Hoffmaster Keith A, Zamek-Gliszczynski Maciej J, Pollack Gary M, Brouwer Kim L R
Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA.
J Pharmacol Exp Ther. 2004 Dec;311(3):1203-10. doi: 10.1124/jpet.104.070201. Epub 2004 Aug 9.
[D-Pen2,D-Pen5]-Enkephalin (DPDPE) is excreted extensively into the bile. Although DPDPE is transported by P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (Mrp2) has been identified as an important mechanism for DPDPE transport across the canalicular membrane of the hepatocyte. The present studies determined the relative impact of Mrp2 and P-gp on the hepatobiliary disposition of [3H]DPDPE in isolated perfused rat livers (IPLs). Perfusate clearance of [3H]DPDPE was not different between livers from control and Mrp2-deficient (TR-) rats. Biliary excretion of [3H]DPDPE in IPLs from Wistar control rats was rapid and extensive. However, when [3H]DPDPE was administered to livers from TR- rats, the rate and extent of excretion decreased significantly. Surprisingly, in the presence of the P-gp inhibitor GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide], biliary excretion of [3H]DPDPE was not inhibited in control livers. In contrast, administration of GF120918 to TR- livers further reduced the maximal excretion rate and decreased net biliary excretion of [3H]DPDPE by 87%. GF120918 administration caused an unexpected increase in perfusate clearance in both control and TR- rat livers. At distribution equilibrium, [3H]DPDPE liver/perfusate partitioning was higher in GF120918-treated livers. Results of pharmacokinetic modeling were consistent with the hypothesis that GF120918 inhibited a [3H]DPDPE basolateral excretion mechanism. Mrp2 is the primary mechanism for [3H]DPDPE biliary excretion, and P-gp facilitates excretion of [3H]DPDPE only in the absence of functional Mrp2. [3H]DPDPE is a substrate for a basolateral efflux mechanism that is sensitive to inhibition by GF120918. These data emphasize the importance of using appropriate model systems and comprehensive pharmacokinetic modeling in elucidating the complex interplay between multiple transport systems.
[D-青霉胺2,D-青霉胺5]-脑啡肽(DPDPE)大量排泄到胆汁中。尽管DPDPE是由P-糖蛋白(P-gp)转运的,但多药耐药相关蛋白2(Mrp2)已被确定为DPDPE跨肝细胞胆小管膜转运的重要机制。本研究确定了Mrp2和P-gp对[3H]DPDPE在离体灌注大鼠肝脏(IPL)中肝胆处置的相对影响。对照大鼠和Mrp2缺陷(TR-)大鼠肝脏中[3H]DPDPE的灌注液清除率没有差异。Wistar对照大鼠IPL中[3H]DPDPE的胆汁排泄迅速且广泛。然而,当将[3H]DPDPE给予TR-大鼠的肝脏时,排泄速率和程度显著降低。令人惊讶的是,在P-gp抑制剂GF120918 [N-(4-[2-(1,2,3,4-四氢-6,7-二甲氧基-2-异喹啉基)乙基]-苯基)-9,10-二氢-5-甲氧基-9-氧代-4-吖啶甲酰胺]存在的情况下,对照肝脏中[3H]DPDPE的胆汁排泄未受抑制。相反,将GF120918给予TR-肝脏进一步降低了最大排泄速率,并使[3H]DPDPE的净胆汁排泄减少了87%。给予GF120918导致对照和TR-大鼠肝脏的灌注液清除率意外增加。在分布平衡时,GF120918处理的肝脏中[3H]DPDPE的肝脏/灌注液分配更高。药代动力学建模结果与GF120918抑制[3H]DPDPE基底外侧排泄机制的假设一致。Mrp2是[3H]DPDPE胆汁排泄的主要机制,而P-gp仅在缺乏功能性Mrp2时促进[3H]DPDPE的排泄。[3H]DPDPE是基底外侧外排机制的底物,该机制对GF120918的抑制敏感。这些数据强调了使用适当的模型系统和全面的药代动力学建模在阐明多种转运系统之间复杂相互作用方面的重要性。